Lucid Diagnostics (NASDAQ:LUCD) Stock Keeps “Buy” Rating at BTIG Research

BTIG Research reiterated their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD) in a research report released on Thursday,Benzinga reports.

LUCD has been the topic of several other reports. Needham & Company LLC reissued a “buy” rating on shares of Lucid Diagnostics in a research report on Thursday, October 1st. Weiss Ratings cut shares of Lucid Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $4.19.

Lucid Diagnostics Trading Up 9.2%

LUCD stock opened at $0.42 on Thursday. The company has a market capitalization of $84.61 million, a P/E ratio of -0.89 and a beta of 1.19. Lucid Diagnostics has a twelve month low of $0.30 and a twelve month high of $1.63. The business has a 50 day simple moving average of $0.61 and a 200-day simple moving average of $0.99.

Lucid Diagnostics (NASDAQ:LUCD) last announced its earnings results on Thursday, November 12th. The company reported ($0.06) EPS for the quarter, meeting analysts’ consensus estimates of ($0.06). The business had revenue of $1.20 million during the quarter, compared to analyst estimates of $1.63 million. Research analysts predict that Lucid Diagnostics will post -0.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Lucid Diagnostics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Pine Valley Investments Ltd Liability Co increased its stake in Lucid Diagnostics by 73.2% in the 1st quarter. Pine Valley Investments Ltd Liability Co now owns 34,283 shares of the company’s stock valued at $39,000 after buying an additional 14,487 shares during the period. Bank of America Corp DE lifted its stake in shares of Lucid Diagnostics by 25.9% in the 1st quarter. Bank of America Corp DE now owns 88,527 shares of the company’s stock worth $102,000 after acquiring an additional 18,212 shares during the period. StoneX Group Inc. purchased a new stake in shares of Lucid Diagnostics in the third quarter valued at about $32,000. Two Sigma Securities LLC purchased a new stake in shares of Lucid Diagnostics in the second quarter valued at about $43,000. Finally, Sequoia Financial Advisors LLC acquired a new position in shares of Lucid Diagnostics during the second quarter worth about $99,000. 74.01% of the stock is currently owned by hedge funds and other institutional investors.

About Lucid Diagnostics

Lucid Diagnostics is a U.S.-based medical diagnostics company focused on identifying esophageal precancer and cancer. Its primary offering is EsoGuard, a DNA-based test designed to detect cellular changes associated with Barrett’s esophagus, a condition that can increase the risk of esophageal cancer. The test is designed to work with EsoCheck, a swallowable balloon device that collects cells from the esophagus for analysis. Together, the products are intended to provide a less invasive approach to evaluating patients for esophageal disease than traditional endoscopic procedures.